JP2014534196A - Ｒ（＋）−ｎ−ホルミル−プロパルギル−アミノインダン - Google Patents

Ｒ（＋）−ｎ−ホルミル−プロパルギル−アミノインダン Download PDF

Info

Publication number
JP2014534196A
JP2014534196A JP2014535789A JP2014535789A JP2014534196A JP 2014534196 A JP2014534196 A JP 2014534196A JP 2014535789 A JP2014535789 A JP 2014535789A JP 2014535789 A JP2014535789 A JP 2014535789A JP 2014534196 A JP2014534196 A JP 2014534196A
Authority
JP
Japan
Prior art keywords
rasagiline
pharmaceutical composition
weight
formyl
propargyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014535789A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014534196A5 (https=
Inventor
サファディ、ムハンマド
フレンケル、アントン
カイザー、マイケル
リチト、ダニト
バハー、エリーザー
リドー—ハダス、ラミー
リドー―ハダス、ラミー
ジョルコフスキー、マリナ
コーエン、レイチェル
Original Assignee
テバ ファーマシューティカル インダストリーズ リミティド
テバ ファーマシューティカル インダストリーズ リミティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by テバ ファーマシューティカル インダストリーズ リミティド, テバ ファーマシューティカル インダストリーズ リミティド filed Critical テバ ファーマシューティカル インダストリーズ リミティド
Publication of JP2014534196A publication Critical patent/JP2014534196A/ja
Publication of JP2014534196A5 publication Critical patent/JP2014534196A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C233/03—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to hydrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
JP2014535789A 2011-10-10 2012-10-09 Ｒ（＋）−ｎ−ホルミル−プロパルギル−アミノインダン Pending JP2014534196A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161545422P 2011-10-10 2011-10-10
US61/545,422 2011-10-10
PCT/US2012/059356 WO2013055687A2 (en) 2011-10-10 2012-10-09 R(+)-n-formyl-propargyl-aminoindan

Publications (2)

Publication Number Publication Date
JP2014534196A true JP2014534196A (ja) 2014-12-18
JP2014534196A5 JP2014534196A5 (https=) 2015-12-03

Family

ID=48042235

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014535789A Pending JP2014534196A (ja) 2011-10-10 2012-10-09 Ｒ（＋）−ｎ−ホルミル−プロパルギル−アミノインダン

Country Status (15)

Country Link
US (1) US9346746B2 (https=)
EP (1) EP2766002A4 (https=)
JP (1) JP2014534196A (https=)
KR (1) KR20140090996A (https=)
CN (1) CN103874487A (https=)
AR (1) AR088297A1 (https=)
AU (1) AU2012323349A1 (https=)
BR (1) BR112014008555A2 (https=)
CA (1) CA2851276A1 (https=)
EA (1) EA201490761A1 (https=)
HK (1) HK1200315A1 (https=)
IL (1) IL231721A0 (https=)
MX (1) MX2014004308A (https=)
WO (1) WO2013055687A2 (https=)
ZA (1) ZA201403043B (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2551481T3 (es) * 2006-02-21 2015-11-19 Teva Pharmaceutical Industries, Ltd. Uso de rasagilina para el tratamiento de atrofia multisistémica
JP5769923B2 (ja) * 2006-04-03 2015-08-26 テバ ファーマシューティカル インダストリーズ リミティド レストレスレッグス症候群の治療のためのラサギリンの使用
CN101557706B (zh) * 2006-12-14 2013-08-07 泰华制药工业有限公司 雷沙吉兰碱结晶固体
EP2234478A4 (en) * 2008-01-11 2013-01-23 Teva Pharma RASAGILINE FORMULATIONS, THEIR PREPARATION AND USE
WO2009151594A1 (en) * 2008-06-10 2009-12-17 Teva Pharmaceutical Industries, Ltd. Rasagiline soft gelatin capsules
SI2451771T1 (sl) 2009-07-09 2014-10-30 Ratiopharm Gmbh Soli rasagilina in njihovi farmacevtski pripravki
AU2010304755A1 (en) * 2009-10-09 2012-05-24 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of Progressive Supranuclear Palsy
EP2515891A4 (en) * 2009-12-22 2013-06-05 Teva Pharma 3-keto-N-propargyl-1-aminoindan
JP2013537530A (ja) 2010-07-27 2013-10-03 テバ ファーマシューティカル インダストリーズ リミティド ラサギリンシトレートの分散物
JP2014534197A (ja) 2011-10-10 2014-12-18 テバ ファーマシューティカル インダストリーズ リミティド Ｒ（＋）−ｎ−メチル−プロパルギルアミノインダン
JP2015529196A (ja) 2012-08-17 2015-10-05 テバ ファーマシューティカル インダストリーズ リミティド ラサギリンの非経口製剤

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3201470A (en) * 1965-08-17 Chsx c cech
JPH09505806A (ja) * 1993-10-18 1997-06-10 テバ・ファーマシューティカル・インダストリーズ・リミテッド Ｎ−プロパルギル−１−アミノインダン、これらの塩、組成物、及びこれらの使用
JPH09510188A (ja) * 1994-01-10 1997-10-14 テバ・ファーマシューティカル・インダストリーズ・リミテッド １−アミノインダン及びこれらの組成物
JPH11512736A (ja) * 1995-09-20 1999-11-02 テバ・ファーマシューティカル・インダストリーズ・リミテッド Ｎ−プロパルギル−１−アミノインダンを含有する安定な組成物
JP2003512426A (ja) * 1999-10-27 2003-04-02 テバ ファーマシューティカル インダストリーズ リミティド 双極性気分障害における躁病の治療のための１−アミノインダンの使用。
WO2011050728A1 (zh) * 2009-10-29 2011-05-05 重庆医药工业研究院有限责任公司 一种稳定的雷沙吉兰组合物

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744500A (en) 1990-01-03 1998-04-28 Teva Pharmaceutical Industries, Ltd. Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof
IL92952A (en) 1990-01-03 1994-06-24 Teva Pharma R-enantiomers of n-propargyl-1-aminoindan compounds, their preparation and pharmaceutical compositions containing them
IL99759A (en) 1991-10-16 1997-06-10 Teva Pharma Mono-fluorinated derivatives of n-propargyl-1-aminoindan, their preparation and pharmaceutical compositions containing them
US5877218A (en) * 1994-01-10 1999-03-02 Teva Pharmaceutical Industries, Ltd. Compositions containing and methods of using 1-aminoindan and derivatives thereof and process for preparing optically active 1-aminoindan derivatives
IL118836A (en) 1996-07-11 2001-01-11 Teva Pharma Pharmaceutical compositions comprising s-(-)-n-propargyl-1-aminoindan
ES2241064T3 (es) 1996-12-18 2005-10-16 Teva Pharmaceutical Industries, Ltd. Derivados de aminoindano.
ES2432117T3 (es) 2002-11-15 2013-11-29 Teva Pharmaceutical Industries Limited Uso de rasagilina con riluzol para tratar la esclerosis lateral amiotrófica
WO2004072250A2 (en) 2003-02-06 2004-08-26 University Of Georgia Research Foundation, Inc. Galacturonosyl transferases, nucleic acids encoding same and uses therefor
WO2006014973A2 (en) 2004-07-26 2006-02-09 Teva Pharmaceutical Industries, Ltd. Pharmaceutical dosage forms including rasagiline
US20090111892A1 (en) 2004-11-24 2009-04-30 Shulamit Patashnik Rasagiline Orally Disintegrating Compositions
WO2006091657A1 (en) 2005-02-23 2006-08-31 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations of improved content uniformity
CA2630037C (en) 2005-11-17 2015-03-31 Teva Pharmaceutical Industries Ltd. Methods for isolating propargylated aminoindans
US7572834B1 (en) 2005-12-06 2009-08-11 Teva Pharmaceutical Industries, Ltd. Rasagiline formulations and processes for their preparation
ES2551481T3 (es) 2006-02-21 2015-11-19 Teva Pharmaceutical Industries, Ltd. Uso de rasagilina para el tratamiento de atrofia multisistémica
JP5769923B2 (ja) 2006-04-03 2015-08-26 テバ ファーマシューティカル インダストリーズ リミティド レストレスレッグス症候群の治療のためのラサギリンの使用
EP1892233A1 (de) 2006-08-18 2008-02-27 Ratiopharm GmbH Neue Salze des Wirkstoffs Rasagilin
CN101557706B (zh) 2006-12-14 2013-08-07 泰华制药工业有限公司 雷沙吉兰碱结晶固体
CN101600346B (zh) 2006-12-14 2013-08-21 泰华制药工业有限公司 雷沙吉兰的单宁酸盐
EP1987816A1 (de) 2007-04-30 2008-11-05 Ratiopharm GmbH Adsorbate eines Rasagilinsalzes mit einem wasserlöslichen Hilfsstoff
CA2698695A1 (en) 2007-09-05 2009-03-12 Teva Pharmaceutical Industries Ltd. Method of treating glaucoma using rasagiline
US8188149B2 (en) 2007-09-17 2012-05-29 Teva Pharmaceutical Industries, Ltd. Use of R(+)-N-propargy1-1-aminoindan to treat or prevent hearing loss
EP2234478A4 (en) 2008-01-11 2013-01-23 Teva Pharma RASAGILINE FORMULATIONS, THEIR PREPARATION AND USE
WO2009151594A1 (en) 2008-06-10 2009-12-17 Teva Pharmaceutical Industries, Ltd. Rasagiline soft gelatin capsules
MX2010013766A (es) 2008-06-13 2011-03-15 Teva Pharmaceutical Ind Ltd Star Rasagilina para modificacion de enfermedad de parkinson.
BRPI0909997A2 (pt) 2008-06-19 2015-10-27 Teva Pharma r(+)-n-propargil-1-aminoindano cristalino, composição farmacêutica, processo de secagem de r(+)-n-propargil-1-aminoindano sólido, processo de preparação de uma composição farmacêutica, processo de produção de um lote validado de um produto de farmaco que contém r(+)-n-propargil-1-aminoindano cristalino e pelo menos um veículo farmaceuticamente aceitável para distribuição e processo de prudução de r(+)-n-propargil-1-aminoindano cristalino
US8334409B2 (en) 2008-06-19 2012-12-18 Teva Pharmaceutical Industries, Ltd. Process for purifying rasagiline base
DE102008064061A1 (de) 2008-12-19 2010-06-24 Ratiopharm Gmbh Feste Zusammensetzung mit dem Wirkstoff Rasagilin
US20100189791A1 (en) 2009-01-23 2010-07-29 Teva Pharmaceutical Industries, Ltd. Delayed release rasagiline malate formulation
SI2451771T1 (sl) 2009-07-09 2014-10-30 Ratiopharm Gmbh Soli rasagilina in njihovi farmacevtski pripravki
AU2010304755A1 (en) 2009-10-09 2012-05-24 Teva Pharmaceutical Industries, Ltd. Use of rasagiline for the treatment of Progressive Supranuclear Palsy
EP2515891A4 (en) * 2009-12-22 2013-06-05 Teva Pharma 3-keto-N-propargyl-1-aminoindan
AU2011282720B2 (en) 2010-07-27 2016-12-22 Teva Pharmaceutical Industries Ltd. Use of rasagiline for the treatment of olfactory dysfunction
JP2013537530A (ja) 2010-07-27 2013-10-03 テバ ファーマシューティカル インダストリーズ リミティド ラサギリンシトレートの分散物
SG189454A1 (en) 2010-10-26 2013-05-31 Teva Pharma Deuterium enriched rasagiline
AU2012323346A1 (en) 2011-10-10 2014-05-15 Teva Pharmaceutical Industries Ltd Rasagiline citramide
JP2014534197A (ja) 2011-10-10 2014-12-18 テバ ファーマシューティカル インダストリーズ リミティド Ｒ（＋）−ｎ−メチル−プロパルギルアミノインダン
JP2015529196A (ja) 2012-08-17 2015-10-05 テバ ファーマシューティカル インダストリーズ リミティド ラサギリンの非経口製剤

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3201470A (en) * 1965-08-17 Chsx c cech
JPH09505806A (ja) * 1993-10-18 1997-06-10 テバ・ファーマシューティカル・インダストリーズ・リミテッド Ｎ−プロパルギル−１−アミノインダン、これらの塩、組成物、及びこれらの使用
JPH09510188A (ja) * 1994-01-10 1997-10-14 テバ・ファーマシューティカル・インダストリーズ・リミテッド １−アミノインダン及びこれらの組成物
JPH11512736A (ja) * 1995-09-20 1999-11-02 テバ・ファーマシューティカル・インダストリーズ・リミテッド Ｎ−プロパルギル−１−アミノインダンを含有する安定な組成物
JP2003512426A (ja) * 1999-10-27 2003-04-02 テバ ファーマシューティカル インダストリーズ リミティド 双極性気分障害における躁病の治療のための１−アミノインダンの使用。
WO2011050728A1 (zh) * 2009-10-29 2011-05-05 重庆医药工业研究院有限责任公司 一种稳定的雷沙吉兰组合物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
JOURNAL OF MEDICINAL CHEMISTRY, vol. 14(4), JPN6016018783, 1971, pages 283 - 286 *
化学増刊９７ 不斉合成と光学分割の進歩, JPN6017015324, 1982, pages 第１５７−１５９頁 *

Also Published As

Publication number Publication date
BR112014008555A2 (pt) 2017-04-18
AU2012323349A1 (en) 2014-05-22
WO2013055687A3 (en) 2013-07-25
NZ624206A (en) 2016-11-25
AR088297A1 (es) 2014-05-21
IL231721A0 (en) 2014-05-28
EP2766002A2 (en) 2014-08-20
EP2766002A4 (en) 2015-07-01
ZA201403043B (en) 2015-08-26
CN103874487A (zh) 2014-06-18
EA201490761A1 (ru) 2014-11-28
HK1200315A1 (en) 2015-08-07
MX2014004308A (es) 2014-07-24
KR20140090996A (ko) 2014-07-18
US20130089612A1 (en) 2013-04-11
WO2013055687A2 (en) 2013-04-18
CA2851276A1 (en) 2013-04-18
US9346746B2 (en) 2016-05-24

Similar Documents

Publication Publication Date Title
JP2014534196A (ja) Ｒ（＋）−ｎ−ホルミル−プロパルギル−アミノインダン
JP2014534197A (ja) Ｒ（＋）−ｎ−メチル−プロパルギルアミノインダン
JP2014534195A (ja) ラサギリンシトルアミド
ES2370980T3 (es) Formulación de resagilina de liberación retardada.
KR20130041193A (ko) 5-클로로-4-하이드록시-1-메틸-2-옥소-n-페닐-1,2-다이하이드로퀴놀린-3-카복스아마이드, 염 및 그의 용도
CN104395291B (zh) N‑乙基‑4‑羟基‑1‑甲基‑5‑(甲基(2,3,4,5,6‑五羟基己基)氨基)‑2‑氧代‑n‑苯基‑1,2‑二氢喹啉‑3‑甲酰胺
JP2020510073A (ja) デューテトラベナジンの類似体、その調製及び使用
DK2506842T3 (en) Formulations, salts and polymorphs of transnorsertraline and their applications
EP2874628A2 (en) Salts and hydrates of antipsychotics
NZ624206B2 (en) R(+)-n-formyl-propargyl-aminoindan

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151009

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151009

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20160519

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160524

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160819

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161018

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161121

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170509

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180123